Loading
Instead of one lab's mouse study deciding whether a drug goes to patients, several labs run the same protocol independently, like a multi-centre clinical trial for mice.
Multi-centre preclinical randomised trials (for example the Multi-PART stroke consortium and EQIPD in Europe) show that effect sizes shrink and heterogeneity appears when protocols are run across sites, exposing fragile findings before they reach patients. In oncology, a standing network of laboratories that runs pre-registered, blinded, multi-site efficacy studies for compounds approaching translation would replace single-lab evidence with robust estimates.
Shares Audit animal studies for randomisation and blinding, published by institution, Patient-derived xenografts, Preclinical results do not reproduce, Lab models that fail to predict what happens in patients.
Shares Champions Oncology, Patient-derived xenografts, Lab models that fail to predict what happens in patients.
Shares Independent replication of the key experiment before first-in-human academic trials, Preclinical results do not reproduce.
Shares Champions Oncology, Patient-derived xenografts, Lab models that fail to predict what happens in patients.
Shares Patient-derived xenografts, Preclinical results do not reproduce, Lab models that fail to predict what happens in patients.
Shares Patient-derived xenografts, Preclinical results do not reproduce, Lab models that fail to predict what happens in patients.
Shares Patient-derived xenografts, Preclinical results do not reproduce, Lab models that fail to predict what happens in patients.
Shares Preclinical results do not reproduce, Lab models that fail to predict what happens in patients.